Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $56.56 which represents a slight increase of $0.50 or 0.89% from the prior close of $56.06. The stock opened at $56.07 and ...

Almost exactly 10 years after the FDA’s initial FDA approval for Bristol Myers Squibb’s Opdivo as the first PD-1 inhibitor in ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

Merck’s high-priced acquisition finally got the nod in the UK for a rare lung condition, and the FDA greenlit an injectable ...

The top 10 patented drugs getting expired in the coming years in the US, include Pembrolizumab, sold under the brand name ...

Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Bristol-Myers ...

NEW YORK – Carsgen Therapeutics on Monday said it plans to seek approval in China for its autologous CAR T-cell therapy satricabtagene autoleucel (satri-cel) in previously treated patients with ...

This strong market position generates substantial cash flows that support shareholder returns. Turning to the specifics, the ...

Halozyme's attempt to acquire Evotec was a bold move to diversify revenue, but was ultimately unsuccessful, impacting HALO's ...

The FDA approved an injectable version of Opdivo, a cancer drug by Bristol Myers Squibb. Axsome plans to seek approval for ...

EastGroup Properties, Inc.  (the "Company", "we", "us" or "EastGroup") announced today its recent business activity. In ...